Clinical trials: Neoadjuvant Treatment
Breast Cancer
Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
This is a prospective, open-label, phase II study evaluating the efficacy and safety of Trastuzumab Rezetecan in combination with pertuzumab in early or locally advanced HER2-positive breast cancer.
- Trial name
- NCT07047755
- Testing
- Trastuzumab Rezetecan, Pertuzumab
- Volunteers
- 48 people
- Sponsor
- Henan Cancer Hospital
Esophageal Squamous Cell Carcinoma
Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
This is a multicenter, open-label, randomized, controlled clinical study to compare the efficacy and safety of cardonilizumab combined with neoadjuvant chemotherapy and surgery versus neoadjuvant chemoradiotherapy and surgery in…
- Trial name
- NCT07699185
- Testing
- Cardonilizumab, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Tongji Hospital
Locally Advanced Rectal Cancer
Neoadjuvant mFOLFOXIRI Chemotherapy Alone for Extramural Vascular Invasion Positive Locally Advanced Rectal Cancer
Extramural Vascular Invasion Positive(EMVI+) is a high risk of distant metastasis for locally advanced rectal cancer(LARC) after resection.
- Trial name
- NCT04170530
- Testing
- mFOLFOXIRI
- Where
- China
- Volunteers
- 51 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells and decrease the need for surgery.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00045630
- Testing
- carboplatin, gemcitabine, paclitaxel
- Where
- 128 sites in United States
- Volunteers
- 77 people
- Sponsor
- SWOG Cancer Research Network
Predictive Cancer Model, Pathologic Complete Response
Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer
The goal of this observational study is to establish a dynamic multi-omics integration model for predicting pathological complete response (pCR) after neoadjuvant treatment in locally advanced (T3-4NxM0) rectal cancer, providing…
- Trial name
- NCT06364371
- Testing
- Medical examination
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Multiple Myeloma
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
The purpose of this study for Phase l is to determine the maximum tolerated dose of panobinostat given in combination with carfilzomib, lenalidomide, and dexamethasone in 28-day cycles as induction (initial) therapy to…
- Trial name
- NCT02802163
- Testing
- Panobinostat, Carfilzomib, Lenalidomide
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Early-Stage Non-Small Cell Lung Cancer
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
The purpose of this study is to assess the safety, tolerability, and surgical feasibility of preoperative Pumitamig-based therapy and other molecules in resectable, Early-Stage Non-Small Cell Lung Cancer
- Trial name
- NCT07871214
- Testing
- Pumitamig, Carboplatin, Cisplatin
- Where
- 50 sites in United States, Australia and 12 more
- Volunteers
- 80 people
- Sponsor
- Bristol-Myers Squibb
Pancreas Cancer
Development of a Prediction Platform for Neoadjuvant Treatment and Prognosis in Pancreatic Cancer Using Organoid
The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process.
- Trial name
- NCT04777604
- Testing
- Organoid
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Samsung Medical Center
Chemotherapy, Radiation Therapy
Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma
The investigators conducted a phase II, prospective, two-arm clinical study to explore the efficacy of Camrelizumab combined with chemotherapy versus chemoradiotherapy for conversion therapy of potentially resectable advanced…
- Trial name
- NCT05821452
- Testing
- Camrelizumab, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fujian Medical University Union Hospital
Pancreatic Neoplasms
Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer
The goal of the present study is to test if in situations of borderline resectable patients a neoadjuvant treatment combining Gemzar-Abraxane and stereotactic radiosurgery could increase the median OS rates above 30 months that…
- Trial name
- CKPancreas (NCT03199144)
- Testing
- Chemotherapy, Stereotactic radiotherapy, Surgery
- Where
- Luxembourg
- Sponsor
- Centre Francois Baclesse, Luxembourg
HIV Infections
A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients
To compare the proportion of patients who sustain suppression of plasma HIV RNA to undetectable levels [AS PER AMENDMENT 09/19/97: below 200 copies/mL by Roche UltraSensitive assay] among the 3 regimens during the maintenance…
- Trial name
- NCT00001084
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 45 sites in United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Breast Cancer
Intelligent Vacuum Assisted Biopsy Immediately Before Surgery As an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer
Neoadjuvant chemotherapy (NAC) is common practice in the primary treatment of breast cancer, leading to a complete pathologic remission (pCR) of the tumor in more than 50% in aggressive tumor types.
- Trial name
- VISION I (NCT04289935)
- Testing
- Vacuum assisted biopsy (VAB)
- Where
- 26 sites in Austria, Germany and 2 more
- Volunteers
- 420 people
- Sponsor
- Klinik Hirslanden, Zurich
Non-Small Cell Lung Cancer
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
This is a Phase II, open-labeled, single-arm, study of neoadjuvant BL-B01D1in combination with Almonertinib followed by adjuvant Almonertinib for the treatment of Patients with EGFR-Mutation Positive Stage II-IIIB Resectable…
- Trial name
- NCT06951464
- Testing
- BL-B01D1, Almonertinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
- Trial name
- NCT06876714
- Testing
- Trastuzumab (Herceptin), Pertuzumab, Echocardiography
- Where
- 702 sites in United States, Puerto Rico
- Volunteers
- 1,524 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastric Cancer
To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
The Purpose of This Study is to Evaluate the Efficacy and Safety of Cadonilimab（AK104） in Combination With SOX as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.
- Trial name
- NCT05948449
- Testing
- S-1, Oxaliplatin, Cadonilimab
- Volunteers
- 37 people
- Sponsor
- Sichuan University
Muscle-invasive Bladder Cancer
Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics
Although neoadjuvant chemotherapy in muscle-invasive bladder cancer has significantly improved oncological outcomes, approximately 50% of patients do not respond to neoadjuvant chemotherapy, which has adverse effects on patients…
- Trial name
- NCT06373055
- Testing
- neoadjuvant chemotherapy followed by radical cystectomy
- Where
- South Korea
- Volunteers
- 250 people
- Sponsor
- Yonsei University
Non-Small Cell Lung Cancer, Anti Angiogenesis
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
This is a Phase II, prospective, randomized, open label, controlled, multi-center study, aim to evaluate the activity of Tislelizumab and Anlotinib and chemotherapy compared with Tislelizumab and chemotherapy before surgery…
- Trial name
- NCT06475755
- Testing
- Immunochemotherapy combined with antiangiogenic, Immunochemotherapy
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Tang-Du Hospital
Resectable Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
This trial is conducted in patients with resectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 46 patients with resectable locally advanced esophageal cancer in Tianjin cancer hospital.
- Trial name
- NCT07457528
- Testing
- HLX10, Chemotherapy, Nimotuzumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colitis, Ulcerative
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis
The purpose of the study is to evaluate the efficacy and safety of LYC-30937-EC given orally once daily in subjects with active ulcerative colitis (UC) defined as a total Mayo score (TMS) of 4-11 inclusive, with an endoscopic…
- Trial name
- NCT02762500
- Testing
- LYC-30937-EC
- Where
- 71 sites in United States, Canada and 5 more
- Volunteers
- 124 people
- Sponsor
- Lycera Corp.
Triple Negative Breast Cancer
Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer
The purpose of this study is to increase survival of patients with locally advanced triple-negative breast cancer using two consequent induction preoperative chemotherapy regimens.
- Trial name
- NCT01969032
- Testing
- Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine
- Where
- Russia
- Volunteers
- 41 people
- Sponsor
- Russian Academy of Medical Sciences
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.